Brief: EMA Recommends Restricting Use Of Tecovirimat SIGA
27/03/2026 11:58
March 27 (Reuters) - EMA: EMA RECOMMENDS RESTRICTING USE OF TECOVIRIMAT SIGA EMA: CHMP HAS RECOMMENDED THAT TECOVIRIMAT SIGA SHOULD NO LONGER BE USED FOR TREATMENT OF MPOX - WEBSITE EMA: REVIEW DID NOT IDENTIFY ANY NEW SAFETY CONCERNS ASSOCIATED WITH TECOVIRIMAT SIGA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SIGA Technologies
See all newsBrief: Siga Secures Contract Valued At Up To $15 Million From Canadian Department Of National Defence To Purchase Tpoxx®
SIGA Technologies Q2 revenue, profit drop as contract ends
SIGA Technologies Q1 revenue falls, net loss widens
Brief: SIGA Technologies Q1 EPS USD -0.05
Brief: EMA Recommends Restricting Use Of Tecovirimat SIGA